-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 ExHMq7SJBkvFVb+ZVbwy0LnGUQsuwa63CrYZj8moeu8pdarINbd/hflgO8vjRh54
 n8FMK/aAK4Kjuh06+zvRWw==

<SEC-DOCUMENT>0000950129-04-007105.txt : 20040916
<SEC-HEADER>0000950129-04-007105.hdr.sgml : 20040916
<ACCEPTANCE-DATETIME>20040916121346
ACCESSION NUMBER:		0000950129-04-007105
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20040915
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040916
DATE AS OF CHANGE:		20040916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBERONICS INC
		CENTRAL INDEX KEY:			0000864683
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				760236465
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19806
		FILM NUMBER:		041033199

	BUSINESS ADDRESS:	
		STREET 1:		100 CYBERONICS CENTER BLVD
		STREET 2:		SUITE 600
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77058
		BUSINESS PHONE:		(281) 228-7200

	MAIL ADDRESS:	
		STREET 1:		100 CYBERONICS  BLVD
		STREET 2:		SUITE 600
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77058
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>h18481e8vk.htm
<DESCRIPTION>CYBERONICS, INC. - DATED 9/15/2004
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B>

<P align="center" style="font-size: 12pt"><B>Date of Report (Date of Earliest Event Reported): September&nbsp;15, 2004</B>

<P align="center" style="font-size: 24pt"><B>CYBERONICS, INC.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other<BR>
jurisdiction of<BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>0-19806</B><BR>
(Commission<BR>
file number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>76-0236465</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>Cyberonics Building<BR>
100 Cyberonics Boulevard<BR>
Houston, Texas 77058</B><BR>
(Address of principal executive offices) (Zip code)



<P align="center" style="font-size: 10pt"><B>(281)&nbsp;228-7200</B><BR>
Registrant&#146;s telephone number, including area code:



<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;2.02 Results of Operations and Financial Condition</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURE</A></TD></TR>
<TR><TD colspan="9"><A HREF="h18481exv99w1.htm">Press Release dated September 15, 2004</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;2.02 Results of Operations and Financial Condition" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;15, 2004, Cyberonics, Inc. (&#147;Company&#148;) issued a press release
announcing that the Company&#146;s Board of Directors, after consulting with its
financial advisor, Merrill Lynch &#038; Co., has unanimously rejected Advanced
Neuromodulation Systems Inc.&#146;s invitation to &#147;meet to discuss a business
combination.&#148; The Company also conducted a conference call during which it
discussed the press release. A copy of the press release is attached as an
exhibit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with General Instruction B.2. of Form 8-K, the Press Release
attached hereto as Exhibit&nbsp;99.1 shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as shall be expressly set forth by specific reference
in such a filing.

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Exhibits



<P align="left" style="margin-left:5%; font-size: 10pt">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release of Cyberonics, Inc. dated as of September&nbsp;15, 2004.

<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>CYBERONICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000">/s/ David S. Wise
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3">David S. Wise&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3">Vice President, General Counsel and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Date: September&nbsp;16, 2004



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>EXHIBIT LIST</B>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release of Cyberonics, Inc. dated as of September&nbsp;15, 2004.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>h18481exv99w1.htm
<DESCRIPTION>PRESS RELEASE DATED SEPTEMBER 15, 2004
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><IMG src="h18481h1848146.gif" alt="(Performance Graph)">



<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99.1</B>



<P align="left" style="font-size: 10pt">For Immediate Release Wednesday, September&nbsp;15, 2004



<P align="center" style="font-size: 10pt">CYBERONICS REITERATES NO INTEREST IN ANY MERGER OR COMBINATION WITH<BR>
ADVANCED NEUROMODULATION SYSTEMS



<P align="center" style="font-size: 10pt"><I>Conference call at 4:30 PM EDT today, September&nbsp;15</I>


<P align="left" style="font-size: 10pt">HOUSTON, Texas, September&nbsp;15, 2004 &#151; Cyberonics, Inc. (NASDAQ:CYBX) today
announced that its Board of Directors, after consulting with its financial
advisor, Merrill Lynch &#038; Co., has unanimously rejected Advanced
Neuromodulation Systems Inc.&#146;s (NASDAQ:ANSI) invitation to &#147;meet to discuss
a business combination.&#148; The Company reconfirms its previously stated
position in its press release dated August&nbsp;20, 2004, that it is not
interested in any combination or merger and remains focused on strengthening
its epilepsy business and gaining clarity and certainty in a revised
depression regulatory plan and timeline.

<P align="left" style="font-size: 10pt">CONFERENCE CALL ACCESS INFORMATION

<P align="left" style="font-size: 10pt">A conference call to discuss this press release will be held at 4:30 PM EDT
today, Wednesday, September&nbsp;15, 2004. To listen to the conference call live by
telephone dial 877-451-8943 (if dialing from within the U.S.) or 706-679-3062
(if dialing from outside the U.S.). The conference ID is 210644; the leader is
Pam Westbrook. A replay of the conference call will be available two hours
after the completion of the conference call on Wednesday, September&nbsp;15, 2004
through Wednesday, September&nbsp;29, 2004 by dialing 800-642-1687 (if dialing from
within the U.S.) or 706-645-9291 (if dialing outside the U.S.). The replay
conference ID access code is 210644.

<P align="left" style="font-size: 10pt">ABOUT VNS THERAPY AND CYBERONICS


<P align="left" style="font-size: 10pt">Cyberonics, Inc. (NASDAQ:CYBX) was founded in 1987 to design, develop and
market medical devices for the long-term treatment of epilepsy and other
chronic neurological disorders using a unique therapy, vagus nerve
stimulation (VNS). Stimulation is delivered by the VNS Therapy System, an
implantable generator similar to a cardiac pacemaker. The VNS Therapy
System delivers preprogrammed intermittent mild electrical pulses to the
vagus nerve 24 hours a day. The Company&#146;s initial market is epilepsy, which
is characterized by recurrent seizures. Epilepsy is the second most
prevalent neurological disorder. The Cyberonics VNS Therapy System was
approved by the FDA on July&nbsp;16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12&nbsp;years
of age with partial onset seizures that are refractory to antiepileptic
medications. The VNS Therapy System is also approved for sale as a
treatment for epilepsy in all the member countries of the European Economic
Area, Canada, Australia and other markets. To date, more than 27,000
epilepsy patients in 24 countries have accumulated over 79,000 patient years
of experience using VNS Therapy. The VNS Therapy System is approved for
sale in the European Economic Area and in Canada as a treatment for
depression in patients with treatment-resistant or treatment-intolerant
major depressive episodes including unipolar depression and bipolar disorder
(manic depression). VNS Therapy is at various levels of investigational
<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">clinical study as a potential treatment for depression, anxiety disorders,
Alzheimer&#146;s disease, and chronic headache/migraine. The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium. For
additional information please visit us at www.cyberonics.com.

<P align="left" style="font-size: 10pt">CONTACT INFORMATION<B>:</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pamela B. Westbrook
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Helen Shik</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vice President of Finance and CFO
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cyberonics, Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Schwartz Communications</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">100 Cyberonics Blvd.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">230 Third Avenue</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Houston, TX 77058
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waltham, MA 02154</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Main: (281)&nbsp;228-7200
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Main: (781)&nbsp;684-0770 ext. 6587</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: (281)&nbsp;218-9332
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (781)&nbsp;684-6500</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">pbw@cyberonics.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">hshik@schwartz-pr.com</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>h18481h1848146.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h18481h1848146.gif
M1TE&.#EAS0!>`/<``.;1*JQS8=K"V?+E'O7N])-*>OS[_.C4*8@VAL2=PNWB
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M^^;5Y/#F[Z)CG].R/=&L0.34Y+Z04,FFQ_KW^OGU^9I3=/;K&_+H\-G`U^?7
MYHT_B+)]6YQ6<_#A.+.`L+)^K_?S^-*ST+%[78U`@//G':IQI_+D'[B&5J!?
M;<^PSG\IC?OX^?CS]_/K\J1G:,JC1<NG0HP]B.#&,:5H9\.;P9]>G(P_@)E2
M<H<U@YQ9F)=/DX`LB_[^_O[]_H@VA(DWA?W\_8@WA/'C((8SB.[>(_W]_8@W
MAOW\_._?(N[>(O[]_?_^__S\_/#A(?#B(?+J\?'C'[!Y7?[__H0PBO+I\88T
MB)%'>__^_O'B(>S?Z]2S.^[?(_GP&/CS^/+C(($KB^[=)/;O]>[?(MB]J-_)
MW;:#6/[]^.W@[-_*W=>W.H8QB/[___[^_;)[78DXA,>?2-"OSO___LFA1_GX
M^;R,4^73Y)M7E^74Y,&14/#?(\2;2L6?P\RE1+.`6H@UA+%Z7_OY^X0NBMO$
MVL*73;B'M?#C((DXA?___R'Y!```````+`````#-`%X```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*$<:4!"'E:4D
M)U*\F.FNT)P.=;`(2<FSI\^&M.BDZ=3`EK^C2),FS94*3()(/Z-*1>G%0QYS
MMY1JW9I4E@8E4\.*S;@&#[^B7-.F90JFCHZQ<.,NQ'6CE0JU>/':6L(BF]R_
M<H?IN``KKV&\L%[4`<QXZIH>DG(=GISV5JXD>AIK3GFLTUW*H+FJ:+!XL^F0
MCR6'7BVZ$-C3L#528&&!M>VM*E+<B,V[HI=+GV\+1ZI"5I'>R!\N*A%\N',5
M+^(DGYY0R(7FSIU;2(&'NO>!%*YG_Q^/U$*K+M^I&V"%G;SV3B/2(Z]UH[![
M][ELQ9#?^TT#U?>1-UHF_,&V1@SM!:C="5L4N-DS?`"HH'MMS.&@9FLD8=2$
M]XU&PH6`T<)-;1P&V$8>\8$8UR*%;%BB>[`LD8:*<-421X(O.M=&$L?0*)8!
M8+B8HX!+E.9C5,,H@6->-3R058"Y2)A6$R4<*14YVT10Q9-IU1!!`!$\X$LN
M54BQ"Y=X(?!```&84896N1QAPSZ&2'%(-U7LHI8%L6!AY4_>5!*,"#BHA0(H
MG`1SA1S^^`*!(X;4X(MAN^P0!#(BL)'4+2@\H8HQO(3*"Q(9J%.`'US9DHL,
M?_8TC`\,3/^300%H;NK*.9Z8,`FJC@*1@3R%YE5I&+IDFA0"JP2#!#``B"&/
M-!\@8<T*SNBY51,7&-!J2K5P0`02'WRR`%>Y.)-!,0!L@D"C$+BA3082,(K7
ML,5J>M0"97(RQ2FNC+O`#BMP4DP+U]1ZE`4G#+(M2L+D\8HQV.0P[E8U!,#)
M!Z=@<)2C;O`"C`D\:*P6O<8>M8LICG@B32[K'N7'#CFL4`6JN#6PP<(G"=+`
M$5<`DX$-+6^ZB2&Z'/!$,QNWRTLP'W\B+U<DV^M+#1-0<\`$URAUQ`,.&(R4
M+2IH@+-)T:B``A/]?$#%Q$FA,`0GV$@A,KM`'&`%`\5\H(X?7OO_$_51"#A`
M!34,!#`W952.31(MD!3F``"\7!%L4@[LD^LDXB#5ZP')#!'MKT\K];<_E@5`
M#2_GS++:B00H+A(M:=CCSQ$2%)/!#I,BE<L#!R`!@"NYTWW`%WX\,06I$AR.
MU.C^^#'$`9X<X'3?:;51"'JN@U3+'4:AT(@N'TA@[5%'1'#Q*:%O_L4R1S`!
M#!(@AV[R#L26[`\"-73C"##82&/#^(;ADY^R]Y%:D&%#1Y`&$AA0`Z3<PA5:
M,,8!;,`VX7VA#+=H'P",80(B(`!-S+N?*^JQ06!,X0H3:`0`TV(!60B`@`4L
MP8;.YHD,)(-M.QA`W)2GOC<=Q08FR-LY_S"X//K52RL(*(`5CC>J#)SC5'B!
MCG1@V)%:S`%`KH!<..3E@$1<;H4]1(HYS'"N#%CA:2$\5@$2`8!B\,(8A9.?
M4J1(Q2I>$2DUD$<Q3%`%7]SB`0SP'?"4$D:D=&H*>XS7_.IG+ZZH:0(,,`:Z
M-*$ZT43G(+3HQ3]H00N!X`(7!,$'/@2BC%H,@Y,"$00H"8*+6FQ2D\_X!3$Z
M*8Q?/.,?O>AD+O^!"P-HLB#X<&4MB/&+5Z:RD_C0I2X%\DN!X&,8FR0&,32Y
MRTTNHI.\Q&8S"5*+2[CH".5`Q@?8L8LC/.%\<BSD43+HOCVR0V-IW,H""G`*
M3GCB"G^@F59:>/\<@P@!$ETX@P<$PH50#,0)@&"!$_YA!`$P0Q]G^`<D^!&'
M%`ED`]+!@I]`(`,-O(4$)=B#1".:!O0`@A]\P*9`%,$/D6[A`JP8`3Y"T3H7
ME.(?+GC#/[@`EGD8X1_SV`E#[Q"?-;C@`MSXQP]@\`\O`,(%'0`+#.[@2E:H
M=""UZ("0LL@L<SA`&AQL1-`T!X&Z75`KOGB>,3"VBY<QTC`+>(`$W("-1$2!
M*]O9S4'.H`$\0.$?T2!!#_@@44C\@P#'J$4V(`$#`>R&KU`A""0`(8`B^(D/
M&I`!'?Y!`C+<0%LD2`,W&/$/%I`!>P,AP3QZ]`\.;'81/]"I&A1Q@R3_*.`?
M&P!+`OR2@)^V-@$*Z"0CTD"!?]2!J3(@[3_N@`MF)"`&:Y#!5052BP0(J082
M,$8&`E``9,1-CA;TH5)R`0H3K+4%LS"B_?`BAR=8HP_T$`5>6P$'A,`@!J6)
M0Q:R0"`!&):O[U@$8QW[CU\0X`<-&@@70'`#->CC'UC@AA<$0@(6;/8?<;@$
M]GYP6X+08B5I8$9K7_N#;"S""7?H0!J@X@00_&.W+_XI(TK``@U,>+C%/>Z+
M=5I:7,"`!#H`A`:FN\E,V.<H*-B!)Z8@C0GD2A,K3)I9Q:L5,WS`=A*H0CR.
M>)0X5:`&!BL#*`[@"#',PFMM`,.%#X((/[TA_PY*T($'1!P*#6A@H?]`Z#S>
MD6=^_(`0!.&"GWJPT$C(@!6`YH(+\+`39J2APRR(`0BNRHH.."$^KOT';*N!
MA3T((!.1\(`7")!9$DPX"])QP6TUH-,1$->X3!5"!]#1`841@@2T4$`'B#P,
M+!SY*`ZX`A*F$$@`."!X25&G4K)B"FP4XP`B.``TC/5(`*B"$OI$BAS&4`Q.
MJ*.12L'6*!&"2F'\LA?"$`@F2$$0(4SX'[400G$)LDM:K*$6REC#*-*-BU[,
M4B`46*6^M_D/`PAAE?^F13%QD4D#*%P@:Q""*_\A"&UIJ\"N?'B!55J*B]-B
ME?,V2#9J=81D("-4'_]H`9637=;AK7Q39S-!$((1C&)0>Q/L<`/(*HF4P/&@
M;A.0[[7(D!`O,$.Y=80(+MPA):Y.PP00&"O+IYRFY[G1YO9RG@D&4+BY(<`<
MFM`%)\)1`:1I!1:I4$1"=$`"%R<=(@84DC^P"XWOID79CBQO,;`..`?H[]D\
M>``.<M$(&A0#&@!(1M:VLIT0)`0&?%C#VR%""RY@QWL#R(`FS+X5O)/+#A_@
M\OTJT((^\$(;'V```&@.OW?V;4<B1H@^YH&)R4.D%'+W1[`/T+6[M_RL><G*
M*L*P7@2XXA/1$E4P@J"*"(`7*6U0@T)`4%_;/P07G9![^UJ0.;4XP!2@<(;_
MU/$R!BO<=;P5>,(7J/")``S!`>-/RFBXH!!]&-;Z#J'%C;1RA#XJ"`4U("6V
ML2,WA1!Z4`>O@7\-P0A+0#U#8ANYH`*`H!"$H`],I8`-@0LL\&L/J!WN,`,*
M40=JAX$.H0,.F!8.,`244`4(@`(/4`%34P`?Y`"4L((+D`LUT`@%`"`X6`'K
MDD$%\`<U@`"^L`D%L`N;X`P/T`C.X``/@`!M8`D+`0<)1H(,@0L:L"0H:`I:
MX`P+X``1$`C+T`CR@`$+T`B'4`55L``+\`<T8`HM(`>W@``5P`[R(%_S-`G)
MT`T1<`U50`5V$`'LX"63``\V<`TGP&<)P04E\!96_]@0;]"`H($`SF!FM^``
M`2`/=G`/^V"&C1`.3``*.-"&^^`,^_!!_W((@;"&\]0YJS`)&.`'=J`*B=`D
MH``*3U``.-`!"H$/.E"`CWB%BJ"%6T&)EHB)J(`&5)`\9[@"8V`#.+`+?\``
M6F`#9>`+:X(&-I`(U[``SI`(*Q`(C>*-5#`!/.</YI&`!Q$-+#!%P<@0C!`+
MN:<6QGAF8"B&9(@!"``!J7,O$*`%`0"+9V@($H`*IU`#NU``]3`&/J0F`?`%
M<X-V'*`0M/`.[?".#F$CQ#A>#^`T<V<#3Y"0FE`&260%:&`*)%D`$_``*YE6
M:(`!#F`&3)`/%;`*.V`MOO\0DW9`,[D`"Y9P<0B!#T7P8!C9$&N@!AS8@9.1
M9K&7$"[`#T7Y$$;@#O.HE'OB0@NQ""#@B%')$+2@!Y)P@E:)%+`@"2[`$"Y@
M(5V9D7A0E6.9%+:``KRX$""@#T2VE@E!"X.P!`+XEEUF"Y:0;E.H5WB9D5C`
MEWXY7K9P"<6T$$,Q#H5)>>_P'XG99?Z0!:ND$'Q0!)(7F1`Q#-'@#K+CE[8@
M"7?@$!Z0`)XY$=EP"2CPEK:0`GBV$+30`ZJYFA-1"UN0`J,Y)+:0"ATP;@MA
M!'$`#KAI$4+``F*9';`0"]V1@81@6<=I$;40"4FPD;<!"PW``<+)$&=0`HHX
MG1;_@0MX4`C8"1JVT`!WP&,.(0`RD`[BJ1&XP`=I<`))&1I[D07<X!</40T"
M0`+?$)\=(0R1P`\O<)]XD0M+,`<>8%$/(03M4`0B):`?@0M*4`>6T`J(R14H
M(`MYP`KOT)D3(0"6`(P4*A(&<`SOH`\>L`%<P`5%,`/?P`C*<!%&<`>G>:+?
M,0,LP`P.JJ.]80!.,`]`ZAU8<%J^5:2]P0SSH`@Z`)1*:B"A8`G9`&A1"AL$
M@`7Z]0;1<*6P\0BA4`<<$*!>NAFXH`!%D``=$`E=6J:`40OK0`>0X`&7@`<3
M*51N.A50@`=&4`2E4%)DL`=@$`EW8`"HE:=BH0"9D`T;$>`%W%`+[(FHDCJI
(E%JIFQ$0`#L_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
